Benethera
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Benethera - overview
Established
2021
Location
Beijing, Beijing, China
Primary Industry
Biotechnology
About
Headquartered in Beijing, China, Benethera is a biopharmaceutical company focused on developing innovative treatments for autoimmune dermatological conditions, leveraging advanced therapy mechanisms to enhance patient care. Founded in 2021, Benethera is dedicated to developing biopharmaceutical solutions for skin inflammation diseases. The company has not undergone any significant strategic pivots and operates independently in its sector. The firm has completed a total of 3 funding rounds, with the most recent funding occurring on May 21, 2026.
Details about the founder or CEO are not available. Benethera specializes in developing and commercializing innovative biopharmaceutical products targeting autoimmune dermatological therapies. Their flagship offering is an external ointment for conditions like dermatitis, psoriasis, and eczema, designed to promote safety and efficacy through a novel pharmacological mechanism. The company serves healthcare providers and pharmacies, primarily within Asian markets, while actively seeking expansion into additional international markets.
Benethera's revenue model focuses on direct sales of its flagship ointment and related products to healthcare professionals and retail pharmacies. Revenue is generated through B2B partnerships with distributors and wholesalers, ensuring competitive pricing aligned with industry standards. The company may also explore subscription models for consistent supply agreements with healthcare facilities, tailored to the unique value of their engineered Tconv cell therapy platform. In May 2026, Benethera secured Series A funding, co-led by Lapam Capital and Fudan Innovation Centre, aimed at supporting the Phase I clinical trial of its core pipeline, BT-101, as well as advancing preclinical research in its cell therapy pipeline.
The company is also planning to launch new products targeting additional autoimmune conditions and expand its market presence into untapped regions, with specific timelines for these initiatives to be defined as the company progresses.
Current Investors
FOF Capital, Lapam Capital, Fudan Innovation Centre
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biotechnology, Healthcare
Website
www.benethera.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.